Characteristics of Patients Treated With RFT5-SMPT-dgA
Patient No. . | Age/Sex . | Histology . | Primary Resistant . | Prior Therapies . | ABMT/PSCT . | Karnofsky . | Stage . |
---|---|---|---|---|---|---|---|
1 | 23/F | LP | N | 5 | N | 50 | IVB |
2 | 27/M | NS | N | 5 | Y | 70 | IVA |
3 | 34/M | NS | N | 8 | Y | 70 | IVB |
4 | 33/M | MC | N | 5 | Y | 50 | IVB |
5 | 31/F | NS | N | 4 | Y | 90 | IVA |
6 | 28/M | NS | Y | 6 | N | 60 | IVB |
7 | 32/F | NS | N | 5 | Y | 80 | IVA |
8 | 19/M | MC | Y | 2 | N | 80 | IVA |
9 | 34/M | NS | N | 6 | Y | 70 | IVA |
10 | 31/M | MC | Y | 5 | Y | 90 | IVA |
11 | 20/F | MC | N | 3 | N | 90 | IIA |
12 | 33/M | NS | N | 3 | Y | 80 | IVB |
13 | 28/M | NS | Y | 3 | N | 60 | IVB |
14 | 29/F | NS | Y | 6 | N | 90 | IVA |
15 | 33/M | NS | N | 3 | N | 90 | IIA |
Patient No. . | Age/Sex . | Histology . | Primary Resistant . | Prior Therapies . | ABMT/PSCT . | Karnofsky . | Stage . |
---|---|---|---|---|---|---|---|
1 | 23/F | LP | N | 5 | N | 50 | IVB |
2 | 27/M | NS | N | 5 | Y | 70 | IVA |
3 | 34/M | NS | N | 8 | Y | 70 | IVB |
4 | 33/M | MC | N | 5 | Y | 50 | IVB |
5 | 31/F | NS | N | 4 | Y | 90 | IVA |
6 | 28/M | NS | Y | 6 | N | 60 | IVB |
7 | 32/F | NS | N | 5 | Y | 80 | IVA |
8 | 19/M | MC | Y | 2 | N | 80 | IVA |
9 | 34/M | NS | N | 6 | Y | 70 | IVA |
10 | 31/M | MC | Y | 5 | Y | 90 | IVA |
11 | 20/F | MC | N | 3 | N | 90 | IIA |
12 | 33/M | NS | N | 3 | Y | 80 | IVB |
13 | 28/M | NS | Y | 3 | N | 60 | IVB |
14 | 29/F | NS | Y | 6 | N | 90 | IVA |
15 | 33/M | NS | N | 3 | N | 90 | IIA |
Abbreviations: NS, nodular sclerosis; MC, mixed cellularity; LP, lymphocyte predominance; N, no; Y, yes; PSCT, peripheral stem cell transplantation.